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Abstract
Background:  Insertional mutagenesis techniques with transposable elements have been popular among
geneticists studying model organisms from E. coli to Drosophila and, more recently, the mouse. One such element
is the Sleeping Beauty (SB) transposon that has been shown in several studies to be an effective insertional mutagen
in the mouse germline. SB transposon vector studies have employed different functional elements and reporter
molecules to disrupt and report the expression of endogenous mouse genes. We sought to generate a transposon
system that would be capable of reporting the expression pattern of a mouse gene while allowing for conditional
expression of a gene of interest in a tissue- or temporal-specific pattern.
Results: Here we report the systematic development and testing of a transposon-based gene-trap system
incorporating the doxycycline-repressible Tet-Off (tTA) system that is capable of activating the expression of
genes under control of a Tet response element (TRE) promoter. We demonstrate that the gene trap system is
fully functional in vitro by introducing the "gene-trap tTA" vector into human cells by transposition and identifying
clones that activate expression of a TRE-luciferase transgene in a doxycycline-dependent manner. In transgenic
mice, we mobilize gene-trap tTA vectors, discover parameters that can affect germline mobilization rates, and
identify candidate gene insertions to demonstrate the in vivo functionality of the vector system. We further
demonstrate that the gene-trap can act as a reporter of endogenous gene expression and it can be coupled with
bioluminescent imaging to identify genes with tissue-specific expression patterns.
Conclusion: Akin to the GAL4/UAS system used in the fly, we have made progress developing a tool for
mutating and revealing the expression of mouse genes by generating the tTA transactivator in the presence of a
secondary TRE-regulated reporter molecule. A vector like the gene-trap tTA could provide a means for both
annotating mouse genes and creating a resource of mice that express a regulable transcription factor in
temporally- and tissue-specific patterns for conditional gene expression studies. These mice would be a valuable
resource to the mouse genetics community for purpose of dissecting mammalian gene function.
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Background
Derived from ancient salmonid fish sequences [1], the
Sleeping Beauty (SB) transposon is a member of the Tc1/
mariner  superfamily of cut-and-paste transposable ele-
ments [2] and has been developed as a vertebrate transfor-
mation tool [3] and germline insertional mutagen [4,5].
We and others have shown that the SB transposon is
highly active in the mouse germline and can generate her-
itable loss-of-function mutations that lead to detectable
phenotypes [4-7].
Data accumulated from spontaneous and engineered
mouse mutations suggests that a significant percentage of
mouse genes are essential for early development. This has
necessitated the creation of various genetic tools for con-
ditional loss- or gain-of-function genetic studies. In Dro-
sophila, the ability to regulate genes in a tissue- or
temporally-specific manner has become one method to
study the function of these genes. Likewise, the ability to
control the expression of an essential mouse gene is one
way to discover its function in tissues that are formed after
lethal phenotypes are manifest. Temporal and spatial con-
trol of gene expression in mutant backgrounds can be
used to determine when a gene product is required during
a developmental process [8-10]. With this in mind, and
taking lessons from the Drosophila  literature on GAL4/
UAS-based  P-element transposon systems [11], we
designed a SB transposon-based gene trap system that
allows us to annotate the expression pattern and function
of mouse genes.
Previous studies using the SB transposon system for gen-
erating insertional mutations in the germline of mice used
various gene- and polyA-trap transposon vectors [4,5].
These vectors were designed to truncate an endogenous
mRNA, incorporate coding sequences for a visible
reporter like β-Galactosidase or green fluorescent protein
(GFP), and report the expression patterns of trapped
genes. If a transcriptional transactivator, similar to GAL4,
were used in place of a visible reporter molecule, a small
amount of the molecule could lead to high levels of a sec-
ondary reporter transgene under control of a responsive
promoter. Analogous to the GAL4/UAS system, the tetra-
cycline-controlled transactivator (tTA) and Tet-response
element promoter (TRE) were developed for mammalian
systems [12].
Here we report the creation of a mutagenic SB-based,
gene-trap transposon vector that can insert into a mouse
gene and express the Tet-off transcriptional transactivator
(tTA) in its tissue- and temporally-regulated manner. The
"gene-trap tTA" can mutate genes and record their expres-
sion patterns for functional annotation as well as create a
mechanism for driving the expression of transgenes in a
regulable manner in vivo. We also report several general
parameters that impact the application of the Sleeping
Beauty transposon system to mouse functional genomics
including analysis of transposon mobilization rates in
several different transgenic lines and the rescue of a
mutant phenotype by remobilization.
Results
Creation of the gene-trap tTA system
A SB transposon-based gene-trap tTA vector was first
designed for and tested in zebrafish embryos [13]. The
gene-trap tTA vector was shown function in somatic tis-
sues of zebrafish and activate a TRE-regulated GFP trans-
gene. T2/GT2/tTA and T2/GT3/tTA (Fig. 1A) are similar to
the earlier gene-trap tTA (GT/tTA) and encode a carp β-
actin splice acceptor, the encephalomyocarditis virus
(EMCV) internal ribosomal entry site (IRES), the Tet-Off®
(tTA) coding sequence (Clontech, Palo Alto, CA), and the
SV40 late polyadenylation signal. Modifications are
described in the Materials and Methods and include an
upgrade to the 'T2' versions of the SB inverted terminal
repeat sequences (ITR), demonstrated to increase transpo-
sition activity in vitro [14], and the addition of stop codon
sequences in each reading frame just upstream of the
IRES. The T2/GT3/tTA transposon vector (Fig. 1A) was
additionally modified to include a splice acceptor from
the mouse hypoxanthine phosphoribosyltransferase gene
(HPRT) and a V5-epitope tag on the opposite strand of the
transposon. This allows the gene trap to disrupt gene
expression upon insertion into a mouse gene in either ori-
entation. If open reading frame one were conserved after
splicing from the endogenous exon, the V5-epitope would
be added to the truncated peptide.
Fig. 1B shows the method by which the gene-trap tTA can
disrupt a mouse gene. When the gene-trap transposon
lands in the intron of a gene, it will intercept splicing from
an upstream exon and incorporate the IRES and tTA ele-
ments to form a bicistronic messenger RNA. Translation
of the endogenous gene peptide is truncated at one of the
stop codons incorporated just upstream of the IRES. The
IRES element allows cap-independent translation initia-
tion from the second open reading frame to produce tTA
from the same mRNA. For the T2/GT2/tTA vector, an
insertion into a gene in the opposite orientation is not
predicted to mutate the gene, however, the T2/GT3/tTA
would interrupt splicing with the HPRT splice acceptor,
but will not express tTA.
Before making transgenic mice, we validated the function-
ality of the gene-trap tTA as a faithful activator of reporter
gene expression in vitro. First, a G418-resistance cassette
was cloned into the T2/GT2/tTA transposon vector to gen-
erate T2/GT2/tTA/SVNeo (Fig. 1C). We then generated a
HeLa cell line harboring a TRE-regulated luciferase trans-
gene. Upon co-transfection of the pT2/GT2/tTA/SVNeoBMC Biotechnology 2006, 6:30 http://www.biomedcentral.com/1472-6750/6/30
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Gene-trap tTA vector design and in vitro testing Figure 1
Gene-trap tTA vector design and in vitro testing A). The T2/GT2/tTA and T2/GT3/tTA vectors. The 'GT2' version is 
capable of mutating genes in one orientation while the 'GT3' version can mutate genes in both orientations upon insertion into 
a gene. (B- BamHI sites ) B) Compared to normal expression (left), when the T2/GT2/tTA SB transposon-based gene-trap 
vector inserts into a gene in the direction of transcription (right), endogenous splicing incorporates the IRES and tTA 
sequences and the bicistronic mRNA is prematurely truncated at the SV40 late polyadenylation site. The bicistronic mRNA 
allows cap-independent translation of the tTA molecule in addition to any peptide encoded by upstream exons. C) A stable, 
TRE-regulated luciferase cell line was created to test the T2/GT2/tTA/SVNeo transposon vector. After co-transfection with a 
plasmid source of transposase, G418R clones were individually expanded for analysis. D) Individual luciferase expression levels 
of G418R clone cell extracts from twelve control (pT2/SVNeo) and fifty gene-trap tTA clones from C. E) Incubation of three 
clones from C in media supplemented with 2 mM doxycycline results in 10- to 100-fold reduction of luciferase expression.
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transposon vector plasmid and a source of SB transposase,
pCMV-SB [1], the gene-trap tTA transposes at random into
the HeLa cell genome. The SVNeo cassette confers G418
resistance to cells that integrate and express the transpo-
son vector, but the gene-trap tTA cassette can intercept
splicing and express tTA only if the transposon lands in an
expressed gene in the correct orientation. Fig. 1D shows
the luciferase activation in sixty-two individual G418-
resistant clone extracts. As a control, a transposon that
contained the same G418 resistance cassette, but not the
splice acceptor-IRES-tTA cassette, did not activate luci-
ferase expression (Fig. 1D, white bars). As expected, only
a subset of T2/GT2/tTA/SVNeo-transgenic clones, 17 out
of 50, showed activation of TRE-luciferase above back-
ground levels.
The activity of tTA is regulable by administering the drug
tetracycline or its analog doxycycline [15]. We tested this
sensitivity by administering doxycycline to three of the
TRE-luciferase activated clones from Fig. 1D. Fig. 1E
shows the doxycycline-dependent repression of TRE-luci-
ferase activation in each clone. Luciferase activity was
reduced approximately two orders of magnitude in
clones, 43 and 44, and about one order of magnitude in
clone 39. Finally, to assure that gene trap tTA activation
was dependent on splicing from an upstream exon of an
expressed gene, 5' rapid amplification of cDNA ends
(RACE) was performed with primers specific to the gene
trap on mRNA extracts prepared from several clones.
Additional file 1 shows the sequence tags, chromosomes
and gene identification obtained for seven clones. In each
case, an upstream exon of the gene is spliced into the
gene-trap tTA at the predicted position (underlined).
These data demonstrate that the tTA molecule can be
expressed from the gene-trap tTA vector in the context of
a trapped gene to activate a TRE-regulated transgene and
that this activation is repressible by the addition of doxy-
cycline. With the prospect of generating mouse strains
with regulated gene-trap tTA activation, we set out to test
the system in vivo.
Parameters affecting germline mobilization rates
Transgenic mice were generated with the T2/GT2/tTA and
T2/GT3/tTA transposon vectors by standard pronuclear
injection (see Materials and Methods). A typical result of
this protocol is the head-to-tail concatenation of trans-
gene units before integrating into the mouse genome to
create a multi-copy array of transgenes in a mouse chro-
mosome. Each transposon transgene concatemer, thus,
serves as a donor site containing multiple substrates for
mobilization by the SB transposase. To determine the
number of gene-trap tTA transposons in each transgenic
line, we performed Southern blot analysis using a restric-
tion digest scheme that resolves the concatemerized trans-
posons to a single band and estimated the number of
copies based on its intensity (see Materials and Methods).
Table 1 shows ten independent transgenic founder lines
with transposon copy numbers ranging from approxi-
mately three to sixty copies. To test for mobilization of the
transposons in the germline, each transgenic line was
crossed to the CAGGS-SB10 transposase-expressing strain
[16]. The resulting doubly transgenic "seed" mice were
outcrossed to wild type animals to observe gene trap
mobilization in the germline. Southern blot analysis on
tail biopsy DNA from offspring of seed mice was used, as
previously described [4,16], to observe the number of new
transposon insertions per gamete. We averaged the inser-
tion data from seed mice from each line to calculate the
likelihood (rate per copy number) that a transposon
could be mobilized from their respective concatemers
(Table 1). The data demonstrates that lines with fewer
copies of the transposon substrate show the lowest mobi-
lization rates. This, however, is not a strict correlation.
This is evident in comparing lines 6632 and 6657, where
the former has fewer copies, but shows a higher per-copy-
transposon mobilization rate of the latter.
The inability to mobilize transposons in transgenic mice
with few transposons in the concatemer is consistent with
our efforts to re-mobilize a single copy insertion in the
genome. We analyzed the mobilization of two independ-
ently generated single copy insertions. Insertion 01-0032
was generated and described in an earlier report [4] and
02A-0016 is a gene-trap tTA insertion identified in an off-
spring of a T2/GT2/tTA seed male (line 4583) as described
below. When SB transposons are excised from a chromo-
some locus during gametogenesis, host DNA repair
machinery typically creates a "footprint" of a few or sev-
eral base pairs while repairing the double-strand-break
gap [17]. We mobilized the insertions 01-0032 and 02A-
0016 by intercrossing doubly transgenic mice that harbor
a single-copy transposon insertion and the CAGGS-SB10
transposase transgene (Fig. 2A). We detected transposi-
tion in about one out of every 100 offspring for either
insertion by PCR amplifying the sequences that flank the
donor site and sequencing to detect a footprint (Fig. 2B).
Notably, remobilization of insertion 01-0032, which
causes an early recessive embryonic lethal phenotype as a
result of disruption of the mouse Slc25a22  gene [4],
restores activity of the gene and rescues the recessive
lethality associated with this insertion as heterozygous 01-
0032/footprint mice are phenotypically normal mice. The
inability to efficiently remobilize a single copy insertion
has been reported elsewhere [6]. For this reason, we incor-
porated loxP sites into the T2/GT3/tTA vector (Fig. 1A),
flanking the mutagenic portion of the gene-trap vector.
Cre-mediated recombination in tissues and in the germ-
line have been demonstrated and are significantly higher
than the 1% mobilization rate we can achieve by remobi-
lizing single copy insertions [18-20]. Thus, a T2/GT3/tTABMC Biotechnology 2006, 6:30 http://www.biomedcentral.com/1472-6750/6/30
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gene trap disruption of a mouse gene might be rescued by
expression of Cre recombinase in a tissue- or germline-
specific manner.
Table 1 also demonstrates that germline mobilization
rates are lower in the female germline when compared to
their male siblings (dashed boxes). Finally, the solid box
shows the difference in transposition rates between two
sibling male seed mice, one hemizygous and one
homozygous for the transposase transgene. While the
SB10+/+ seed male did not show increased transposition
over other independently generated seed mice for the
4563 line, there was an increase over its sibling SB10+/-
seed male, suggesting that we may be able to increase
transposition rates by increasing the transposase dosage in
future studies. The analysis of several transposon-trans-
genic lines has thus revealed parameters that affect trans-
position rates, and suggest careful line selection will be
required for mutagenic programs.
Sleeping Beauty-mediated gene insertion in vivo
T2/GT2/tTA line 4563 and T2/GT3/tTA line 6660 were
useful to identify new transposon insertions in the off-
spring of seed mice. Techniques for cloning transposon-
genomic DNA junction sequences have been described
[1,4,21]. The chromosomal positions of thirty transposi-
tion events in offspring of seed mice from line 4563 were
identified by querying the ENSEMBL online mouse
genome database using the BLAST function. The T2/GT3/
tTA line 6660 was used in a study of mutations induced
specifically on mouse chromosome 11 and the insertion
data from this line will be reported elsewhere (A.M.G.,
manuscript in preparation). Additional file 2 and addi-
tional file 3 show the data accumulated from the thirty
T2/GT2/tTA events. Consistent with previous reports, the
T2/GT2/tTA transposons exhibit local hopping, where a
significant percentage of new insertions cluster in a partic-
ular region of the genome, and the insertions can land in
genes [4,5]. Three-primer PCR [3] can readily be used to
Table 1: Mobilization of gene-trap tTA transposons in the germlines of seed mice.
Vector Line Chr. (Pos) Copy No. a Seed Mice
(T2+/-;SB10+/-)
Offspring New Hitsb Hits/Gamete Rate/Copy No.c
4555 ND 3 M 10 0 <1:10 NA
F 13 0 <1:13
M 10 14 1.40
M 19 23 1.21
4563 ND 50 F 10 6 0.60 0.019
M (SB10+/+) 10 12 1.20
M 11 3 0.27
T2/GT2/tTA M 33 24 0.73
M 12 10 0.83
M 84 0 . 5 0
M 19 10 0.53
4583 ND 60 F 81 0 . 1 3 0.008
M 17 13 0.76
F (pT2 +/+) 81 0 . 1 3
M 10 3 0.30
4587 ND 10 M 21 0 <1:21 NA
6630 ND 4 M 20 1 0.05 0.020
M 18 2 0.11
6632 6 (B3-C1) 5 M 15 20 1.33 0.267
6657 7 (A3-B2) 10 M 18 8 0.44 0.044
F 10 10 1.00
T2/GT3/tTA 6660 11 (B5-C) 27 M 72 6 3 . 7 1 0.098
M 10 18 1.80
M 16 43 2.69
M 26 79 3.04
M 16 59 3.69
6682 3 (E1-E3)
10 (C3-D1)
11 M 16 6 0.38 0.063
6683 9 (F1-F2) 6 M 14 14 1.00 0.091
a Transposon copy number for each transgenic line was determined by Southern blot (see Materials and Methods)
b The number of single-copy insertions as determined by the presence of new bands on a Southern blot after mobilization by transposase in the 
germline of seed mice
c Reported is the average hits/gemete divided by the copy numberBMC Biotechnology 2006, 6:30 http://www.biomedcentral.com/1472-6750/6/30
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genotype carriers for any specific transposon insertion.
Because we were interested in testing the function of the
gene-trap tTA vector in the context of an endogenous
mouse gene, carriers of insertions 02A-0001 and 02A-
0002, both in mouse genes, (Fig. 3A) were propagated for
further study.
Molecular characterization of gene-trap tTA function
Insertion number 02A-0001 is in the first intron of the car-
bonic anhydrase-12 gene (Car12), while 02A-0002 is
inserted into intron 8 of the predicted novel gene
ENSMUSG00000066992 (Fig. 3A). The top panel in Fig.
3B shows the expression pattern of mouse Car12  by
reverse-transcriptase PCR (RT-PCR) on RNA extracts from
several wild type tissues using primers in exons 1 and 5. If
the gene trap is splicing properly, the IRES and tTA
sequences should be fused to exon 1 of the Car12 mRNA.
The second panel shows RT-PCR detection of endogenous
Car12 and Car12-IRES-tTA bicistronic transcripts in RNA
samples taken from a heterozygous carrier of insertion
02A-0001. Nested PCR was necessary to detect the fusion
transcript in some tissues. Comparing the wild type
expression pattern of Car12 mRNA and the fusion tran-
script, it is apparent that expression of the trapped mRNA
Phenotypic rescue by transposon mobilization Figure 2
Phenotypic rescue by transposon mobilization A). Breeding scheme to remobilize a transposon insertion, 01-0032, out 
of the mouse Slc25a22 gene as previously reported by Carlson, et al . (2003). Animals for both the single-copy transposon 
insertion 01-0032 and the CAGGS-SB10 transposase were intercrossed. B) Germline single-copy remobilization rates of the 
independently generated insertions 01-0032 and 02A-0016 (Additional file 2) were detected by analyzing the donor site for evi-
dence of a transposon footprint by sequencing (data not shown).
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Molecular characterization of gene-trap tTAfunction Figure 3
Molecular characterization of gene-trap tTAfunction A). Insertions 02A-0001 in the mouse Car12 gene and insertion 
02A-0002 in the mouse ENSMUSG00000066992 gene. Genes are shown in the orientation of transcription from left to right, 
vertical lines are exons, along with the position and orientation of the T2/GT2/tTA insertion (arrows). B) RT-PCR detection of 
Car12 (top) and Car12-IRES-tTA chimeric (bottom) transcription in wild type and 02A-0001 carrier tissues. Kd-kidney, Br-
brain, Lv-liver, Te-testes, Ad-adipose, Co-colon,SI-small intestine, Ov-ovary, Mu-muscle, Ht-heart C) RT-PCR analysis of 
gene disruption in tissues from wild type (+/+), heterozygous (+/ins), and homozygous (ins/ins) carriers of insertions 02A-0001 
and 02A-0002. C) Western analysis of CA-XII expression in a wild type, heterozygous and homozygous carrier of insertion 
02A-0001. Cross-reaction of the CA-XII antibody with other isoforms serves as a loading control (arrowhead).
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is tissue specific as predicted. The fusion transcript can be
detected in the heart of the carrier, but not wildtype heart
RNA extracts. We attribute this to the extra sensitivity of
the nested PCR and suspect that endogenous Car12  is
expressed in the heart at a low level.
If the carp β-actin splice acceptor is efficient, it should
truncate the endogenous gene mRNA after the nearest
upstream exon. Total RNA extracts from wild type, and
heterozygous or homozygous carriers of both insertions
02A-0001 and 02A-0002 were probed for expression of
endogenous Car12 or ENSMUSG00000066992 tran-
scripts respectively. Fig. 3C shows complete ablation of
Car12 mRNA in the kidney and brain of a homozygous
carrier of insertion 02A-0001. Expression of
ENSMUSG00000066992, detectable by RT-PCR exclu-
sively in mouse brain (data not shown), was not ablated
in homozygous carriers of insertion 02-0002, however,
suggesting that the carp β-actin splice acceptor does not
work efficiently in each case.
Interestingly, Car12 mutant mice demonstrate reduced fit-
ness, as an intercross of 02A-0001 carriers results in non-
mendelian inheritance of the homozygous class (data not
shown). The expression of the carbonic anhydrase (CA-
XII) has been previously localized to the membranes of
mouse kidney, colon, and testes [22]. The CA-XII peptide
has been previously reported to be 46 kDA [23]. Fig. 3C
shows the reduction of CA-XII expression in the hetero-
zygous kidney and absence in the homozygous kidney.
Antibody cross-reaction with a ~ 30-kDa peptide is con-
sistent with cross-reactions previously seen in kidney
extracts with this antibody [23], and serves as a loading
control (arrowhead, Fig. 3C).
Tissue-specific activation of a TRE promoter-regulated 
transgene in vivo
The final in vivo test for the gene-trap tTA system is to
determine whether the vectors can activate a TRE pro-
moter-regulated transgene in a tissue-specific manner. We
obtained the Tg(tetL)1Bjd/J strain of mice, transgenic for
a TRE-regulated luciferase transgene, from Jackson Labo-
ratories. These mice have been previously shown to
respond to tissue-specific tTA expression in a doxycycline-
dependent manner [24]. Luciferase activity assays from
individual organ extracts from a 02A-0001; Tg(tetL)1Bjd/
J doubly transgenic animals showed activation of luci-
ferase in all tissues tested when compared to singly trans-
genic controls (data not shown). This result was surprising
because the trapped gene, Car12, is not expressed in the
liver (among other tissues) by RT-PCR (Fig. 3B). Insertion
02A-0001 is the result of local transposition, and thus is
linked to the original concatemer of transposons. We rea-
soned that these linked T2/GT2/tTA transgenes present in
carriers of this insertion might express tTA, therefore
resulting ubiquitous luciferase expression when crossed to
the Tg(tetL)1Bjd/J strain. To circumvent this issue, we
focused on insertions that were not the result of local hop-
ping and would segregate from other transposable ele-
ments. Insertions 02A-0002, 03A-0184, 03A-0217, and
03A-0241 (Figs. 3A and 4A) are the result of non-local
transposition of T2/GT2/tTA or T2/GT3/tTA transposons
in their respective transposon transgenic strains. Carriers
of each of these gene insertions were crossed to the
Tg(tetL)1Bjd/J strain of mice with the hope of visualizing
tissue-specific, tTA-dependent transactivation of luci-
ferase. As predicted, Fig. 4B shows weak activation of luci-
ferase in the brain of a 02A-0002; Tg(tetL)1Bjd/J doubly
transgenic mice, but not other tissues. This pattern was
reproduced in three out of four mice. As shown above,
this insertion does not completely disrupt the brain
expression of ENSMUSG00000066992  (Fig. 3C), but
some splicing into the T2/GT2/tTA splice acceptor must
occur to allow tissue-specific expression of the tTA.
Hasan, et al. (2001) demonstrated that non-invasive
imaging of luciferase expression of a similar tTA-activated
strain using an intensified charge-coupled device camera
system after subcutaneous injection of luciferin substrate
[25]. We used the Xenogen IVIS™100 Imaging System to
see if tissue-specific patterns could be detected in gene-
trap tTA; Tg(tetL)1Bjd/J doubly transgenic mice. Light
emissions are often observed in the extremities, nose, ears,
and tails of control Tg(tetL)1Bjd/J in a tTA-independent
manner in our hands (Fig. 5A). No additional tissue-spe-
cific signals were initially detected in 02A-0001;
Tg(tetL)1Bjd/J or 02A-0002; Tg(tetL)1Bjd/J doubly trans-
genic mice, suggesting that expression of luciferase levels
detected in the organ extracts were not sufficient to be
detected by the imager. Likewise, when crossed to the
Tg(tetL)1Bjd/J strain, insertions 03A-0184 and 03A-0217
(Fig. 4A) showed no activation of luciferase by imaging or
by luminometer readings of organ extracts (data not
shown). While the expression pattern of Membrane-span-
ning 4-domains, subfamily A, member 6C (Ms4a6c) is not
characterized, Integrin beta 3 (Itgb3) has been localized to
the developing mouse heart in early embryonic stages
[26]. It is possible that we missed the expression of these
gene-trap tTA insertions because these genes are not
expressed in adult tissues.
In contrast, a striking pattern of luciferase expression was
captured by imaging 03A-0241; Tg(tetL)1Bjd/J doubly
transgenic mice (mouse 936) when compared to singly
03A-0241 transgenic (mouse 933) or Tg(tetL)1Bjd/J con-
trols (Fig. 5A). Light emission patterns were detected from
anatomical origins corresponding to the sternum, spleen,
femurs and vertebrae, presumably reflecting luciferase
activation in a component of the bone marrow and
hematopoietic cells. The MacF1 gene has more than 100BMC Biotechnology 2006, 6:30 http://www.biomedcentral.com/1472-6750/6/30
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exons and has been reported to be expressed in multiple
isoforms in the mouse with high levels produced in the
lung [27]. Using primers in exons that flank the 03A-0241
insertion to amplify MacF1 transcripts, Fig. 5B demon-
strates that at least two splice variants of different sizes are
variably expressed in several tissues, but MacF1 is not nor-
mally expressed in the bone marrow of a wild-type mouse.
This suggests that the 03A-0241 insertion into MacF1 may
cause abnormal expression of the gene in the bone mar-
row and hematopoietic cells. However, multiple attempts
to amplify the chimeric MacF1-IRES-tTA transcript from
bone marrow extracts from carrier mice by RT-PCR were
unsuccessful in identifying this spliced transcript.
To determine whether this pattern was linked only to
insertion 03A-0241 and the mouse MacF1 gene, Southern
blots and genotyping PCR were performed on mouse 936
(and siblings 931–935) and his offspring (mice 949–976)
(Fig. 5C). Surprisingly, mice that inherited insertion 03A-
0241 by PCR showed linkage to the concatemer donor site
by Southern blot (Fig. 5A, arrowhead). This was unex-
pected because these mice were generated from T2/GT3/
T2/GT3/tTA gene disruptions and tissue-specific activation of a tet-responsive transgene in vivo Figure 4
T2/GT3/tTA gene disruptions and tissue-specific activation of a tet-responsive transgene in vivo A). T2/GT3/tTA 
insertions into mouse genes not linked to the original donor site. The genes are shown in the orientation of transcription with 
vertical lines as exons (from left to right) with the position and orientation of the IRES-tTA trapping cassette (arrow). B) Luci-
ferase assays performed on individual tissues from four independent 02A-0002; Tg(tetL)1Bjd/J doubly transgenic and control 
Tg(tetL)1Bjd/J mice.
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In vivo imaging of gene-trap tTAactivation of a tet-responsive transgene Figure 5
In vivo imaging of gene-trap tTAactivation of a tet-responsive transgene A). Luciferase emission pattern seen in a 
03A-0241; Tg(tetL)1Bjd/J doubly transgenic mouse (936) as imaged by an intensified charge-coupled device (CCD) camera. 
Ventral and dorsal aspects are shown. The intensity of luciferase expression is compared in photons/second/cm2. B) RT-PCR 
analysis of MacF1 expression in multiple adult tissues, Gapdh was used as a control for sample quality. ES-embryonic stem cells, 
Lv-liver, Kd-kidney, Br-brain, Lu-lung, Ht-heart, Sp-spleen, St-stomach, BM-bone marrow, SI-small intestine, Co-colon, 
Ad-adipose, Mu-muscle, Ov-ovary, b-testes, Th-thymus C) Southern analysis of mice from A and B (see Materials and Meth-
ods). The donor site concatemer appears as an intense BamHI fragment at 2236 base pairs (arrowhead). The detection of 
insertion 03A-0241 by three-primer PCR is shown below each lane. Three bands marked by arrows segregate with insertion 
03A-0241 genotyping and the concatemer.D) Pattern inheritance by offspring of mouse 936. Mice were imaged and scaled to 
different ranges of intensity that ranged from 1x104 to 1×108 photons/second/cm2 (scale bars). E) Repression of in vivo luci-
ferase activation after six days of treatment with doxycycline in the same mice from D.
936 933
Tg(tetL)1Bjd/J 
controls
962 963 964 971 972 973
962 963 964 971 972 973
A
B
C
D
9
3
1
9
3
2
9
3
3
9
3
4
9
3
5
9
3
6
9
4
9
9
5
0
9
5
1
9
5
2
9
5
3
9
5
5
9
5
4
9
5
6
9
5
7
9
5
8
9
5
9
9
6
0
9
6
1
9
6
2
9
6
3
9
6
4
9
6
5
9
6
6
9
6
7
9
6
8
9
6
9
9
7
0
9
7
1
9
7
2
9
7
3
9
7
4
9
7
5
9
7
6
PCR 
03A-0241 
insertion
-++--+ + + ----+ ----+ ++ + --+++-- ++++++
E
ES Lv Kd Br Lu Ht Sp St BM SI Co Ad Mu Ov Te Th
MacF1
GapdhBMC Biotechnology 2006, 6:30 http://www.biomedcentral.com/1472-6750/6/30
Page 11 of 15
(page number not for citation purposes)
tTA line 6660 (Table 1), which has a transposon donor
site on mouse chromosome 11. MacF1  is located on
mouse chromosome 4 at 57.4 cM, thus the Southern data
suggests that a large portion of the chromosome-11 con-
catemer had translocated by some mechanism to chromo-
some-4. Thus, the MacF1 insertion on chromosome 4 is
still genetically linked to a translocated donor concatemer
of multiple T2/GT3/tTA transposons in addition to other
linked single-copy insertions (Fig. 5C, arrows). Repeated
attempts to identify these other linked chromosome-4
insertions by our cloning techniques and 5'RACE for
trapped sequences in bone marrow extracts were unsuc-
cessful in identifying the origin of this tissue-specific gene-
trap tTA expression. Nevertheless, the pattern seen in 03A-
0241; Tg(tetL)1Bjd/J mice is unique to these mice, as it is
not seen in carriers of other T2/GT2/tTA or T2/GT3/tTA
insertions (with or without associated concatemers) when
crossed to the Tg(tetL)1Bjd/J strain (above and data not
shown).
The tissue-specific luciferase pattern in carriers of this
insertion could be reproducibly transmitted through the
germline to offspring (mice 962–964 and 971–973, Fig.
5D). The upper range of luciferase activation from each
offsrpring, measured in photons/second/cm2, ranged
approximately a thousand-fold (scale bars). We attribute
these differences to differences in the levels of cap-inde-
pendent translation of the tTA molecule from the IRES in
each mouse. Finally, other groups have demonstrated in
vivo sensitivity of tTA-dependent activation of gene expres-
sion to tetracycline, or its analog doxycycline [24,28,29].
We determined whether we could control gene-trap tTA
activation of luciferase by administering doxycycline to
the drinking water of the 03A-0241; Tg(tetL)1Bjd/J mice.
Fig. 5E demonstrates absence of luciferase signal in the
same animals from Fig. 5D, after six days of treatment,
suggesting complete repression of the tTA-dependent luci-
ferase activation.
Discussion
We examined the utility of a SB transposon-base gene trap
vector that expresses the Tet-off transcriptional transacti-
vator in the patterns of trapped genes in vitro and in vivo.
The gene-trap tTA demonstrated full utility in cultured
cells, having the ability to insert in genes, trap the splicing
of those genes to express the tTA transcription factor
which, in turn, could activate a TRE-regulated transgene in
a doxycycline-dependent manner. Likewise, analysis of
gene-trap tTA transposon insertions into mouse genes
revealed that the vector system can completely disrupt the
expression of a mouse gene in some cases and can tissue-
specifically activate expression of a TRE promoter-regu-
lated transgene in a doxycycline-dependent manner in
vivo. While ultimately this vector system can function as
designed, several observations suggest we need a more
optimal approach for creating a resource of mice that
express tTA in developmentally-controlled patterns.
Germline SB transposon mobilization rates in the mouse
germline are variable and ranged from less than one in
twenty to nearly three events per gamete. An evaluation of
several different transposon-transgenic lines has given us
insight into the potential the SB system to perform
regional mutagenesis throughout the genome. The
genomic location of the transposon donor site, along with
copy number, impacts the germline mobilization rate
from any concatemer (see Table 1). This suggests that not
all parts of the genome are equally accessible to SB trans-
position. Understanding the mechanisms behind this
"mobilization position effect" will likely require an
increased understanding about molecular regulators of SB
transposition, but may include a well known director of
position effect, heterochromatinization [30].
As demonstrated in previous studies and here, SB transpo-
son-based gene trap vectors can function in vivo to disrupt
the expression of mouse genes. The T2/GT2/tTA vector
can completely ablate the expression of a mouse gene as
demonstrated by the null mutation that was generated in
the mouse Car12 gene. Not all gene insertions completely
disrupt gene expression however, as in the case of inser-
tion 02A-0002 into ENSMUSG00000066992. While
hypomorphic mutations may be valuable to discover the
function of an essential mouse gene, this has lead to ideas
on how to improve the efficacy of future vectors. Splice
acceptors derived from different genes, termination
sequences (polyadenylation signals) and other functional
sequences have been used in several ES cell plasmid- and
retroviral-based gene-trapping studies with varying effi-
ciencies [31-33]. Drawing data from other groups will
lead to improved vectors for trapping mouse genes and
perhaps lead to vectors to trap certain classes of genes
[34].
The activation of luciferase by the tetracycline-controlled
transactivator varied rougly 1000-fold (Fig. 5D) when
expressed from the IRES in the gene-trap tTA. Once again,
improvements to the functional components of the gene
trap vector may lead to more reliable and greater expres-
sion of the transactivator. Alternative IRES elements like
the 9-nucleotide IRES element from the murine Gtx
homeodomain gene [35], or eliminating the IRES entirely,
may allow for more consistent tTA expression.
The brilliant pattern of in vivo luciferase expression seen if
Fig. 5 was initially thought to originate from insertion in
the MacF1 gene. Published reports suggested that neither
the bone marrow, nor hematopoietic cells are in the nor-
mal expression domain of this gene. Upon further molec-
ular characterization, we discovered that this gene was notBMC Biotechnology 2006, 6:30 http://www.biomedcentral.com/1472-6750/6/30
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spliced into the gene-trap tTA, and by Southern blot,
found it was tightly linked to other insertions as well as
the concatemer. It seems more likely that the pattern of
tTA-dependent luciferase activation seen in carriers of the
03A-0241 insertion comes from one of these linked trans-
posons. Efforts to find the source of this expression by
5'RACE were unfortunately unsuccessful. We propose that
in the case of insertion 03A-0241, the concatemer translo-
cated to chromosome 4 first, then a single copy of T2/
GT3/tTA hopped locally into MacF1. We have observed
similar and other types of genomic rearrangements asso-
ciated with transposition from the chromosome-11 donor
site in other mice (A.M.G., manuscript in preparation).
These observations would suggest that gene-trap tTA
mobilization in the germline may not be the most effi-
cient means of generating a resource of mice with tissue-
specific tTA expression patterns. It is not clear, however,
that these large donor site insertions are not rare events
that could be tolerated. Independent insertions, unlinked
to the concatemer or other transposons, are frequently
recovered. By pre-selecting mice that do not inherit the
concatemer by Southern blot or PCR analysis, a screen
would largely avoid the complications of linked trans-
posons.
An alternative and relatively facile approach would be to
inject a linearized plasmid harboring the gene-trap tTA
transposon, along with in vitro-transcribed transposase
messenger RNA, into one-cell mouse embryos. In the one-
cell embryo, the transposase mRNA is translated and
transposase catalyzes integration into the mouse genome
at rates that are two to three-fold higher than standard
pronuclear injection of naked DNA [3]. This method pro-
duces transgenic mice with insertions distributed ran-
domly across the genome, and multiple linkage groups
are frequently obtained from a single injection [3]. This
would be another method to avoid the complications of
linked insertions and concatemers.
Finally, using the GAL4/UAS enhancer trap systems used
in the fly, expression-based screening has been useful for
identifying genes with similar or overlapping expression
patterns [36] and for tissue-specific overexpression studies
[37]. As we have shown here, a transgenic mouse express-
ing firefly luciferase under the control of the tet-response
enhancer/promoter (TRE) can be coupled with the gene-
trap tTA system to identify in vivo patterns with an inten-
sified CCD camera system. In a screen, this type of imag-
ing could be used to identify gene trap insertions that lead
to tTA expression in a particular tissue or developmental
stage, even in utero [38,39]. Alternatively, mouse strains
for other TRE-regulated transgenes have been created,
allowing for tTA-dependent expression of β-galactosidase
[40] or GFP [41]. If the efficiency of the gene-trap tTA
transposon can be improved, these strains could be used
by any lab to identify tissue-specific patterns.
Conclusion
As a tool for the mouse community, introducing a gene-
trap tTA vector into mouse genes with different spatial and
temporal expression patterns would create a valuable tool
for the mouse genetic toolbox. Tissue-specific promoters
can control the expression of transactivators like tTA and
rtTA (reverse tetracycline-controlled transactivator) in
transgenic animals [42-44]. Having tissue-specific and
temporal control of gene expression in any mouse tissue
at any developmental stage could allow for the dissection
of biological gene functions that were previously masked
by a phenotype such as lethality. An SB-based transposon
vector is well suited to accomplish this task by introducing
precisely integrated functional reporter units into the
mouse genome. In addition, an improved gene-trap tTA
could provide more reliable expression of the transactiva-
tor than a transgene construct since transcription is regu-
lated in the context of an endogenous gene and is thus less
likely to be subject to the position effect variegation that
can hinder the expression of transgenes.
Methods
Cloning gene-trap tTA transposon vectors
All primer/oligo sequences for PCR and cloning are pro-
vided in Additional file 4. All gene-trap tTA vectors are
descendent of pGT/tTA, originally described in Clark et al
. 2004 [13]. An artificial exon (based on carp β-actin exon
2), with stop codons in each reading frame, was created by
annealing four oligos (AMG049-AMG052), filling in the
gaps with Klenow DNA polymerase, ligation with T4 DNA
ligase, PCR amplifying with AMG049 and AMG051, and
subcloning the AgeI fragment into the partially-digested
SmaI-AgeI fragment of pGT/tTA to create pGT2/tTA. Sub-
cloning the exonuclease-treated EcoRV-PstI fragment of
pGT2/tTA into the Klenow-treated blunt HindIII fragment
of pT2/HindIII [14] generated pT2/GT2/tTA. pT2/GT2/
SVNeo was created by subcloning the Klenow-treated Hin-
dIII fragment of pT2/SVneo [14] into the EcoRV fragment
of pT2/GT2/tTA.
The construction of pT2/GT3/tTA was a multi-step process
to add additional features to the GT2 version. First, an
NheI site was added to pT2/GT2/tTA by PCR amplifying
the entire plasmid with primers AG023 and AG024, con-
taining a 12-bp overlap containing the NheI site sequence,
and transformation. E. coli repairs the plasmid by homol-
ogous recombination in the overlapped region, resulting
in the plasmid pT2/GT2/tTA/NheI. A loxP site was made
by annealing two oligos (AG025 and AG026) containing
the 34-bp loxP sequence with overhanging 4-base cohe-
sive ends to NheI and cloned into the NheI site of pT2/
GT2/tTA/NheI, destroying the NheI site on one side, andBMC Biotechnology 2006, 6:30 http://www.biomedcentral.com/1472-6750/6/30
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adding the loxP sequence to make pT2/GT2/tTA/loxP. The
NheI-SpeI fragment of pT2/GT2/tTA/loxP was subcloned
into the XbaI fragment of the transposon vector pT2/HB,
which has a multiple cloning site, to create pT2/GT2/tTA/
loxP-2. 70-mer oligos (SA/V5-1 and SA/V5-2) containing
the HPRT splice acceptor and V5 epitope tag with EagI
compatible ends were annealed and cloned into the EagI
site of pT2/GT2/tTA/loxP-2 to make pT2/GT2/tTA/loxp/
SA-V5. In the process, one side of the EagI site was
destroyed, leaving a single EagI site. A 32-bp transcrip-
tional termination sequence from the human GASTRIN
gene was created by overlapping oligos (Termin-1 and
Termin-2) and cloned into this EagI site of pT2/GT2/tTA/
loxp/SA-V5 to make pT2/GT2/tTA/loxp/SA-V5/Termin.
This sequence was shown to enhance transcriptional ter-
mination in plasmid vectors when downstream of polya-
denylation signals [45], and was included to increase the
chances of mRNA truncation, and thus mutation, in the
gene trap. Finally, a second loxP site was made by anneal-
ing the same oligos above and ligation into the SpeI site of
pT2/GT2/tTA/loxp/SA-V5/Termin to make the final prod-
uct, pT2/GT3/tTA.
Generation of Tre-Luciferase/Puro cell line and in vitro 
gene trap testing
pTRE-Luc was kindly provided by Dr. Perry Hackett's lab
and was co-transfected with the plasmid pKO Select-Puro
(Stratagene, La Jolla, CA) into HeLa cells using Mirus
TransIT-LT1 reagent (Promega, Madison, WI). After puro-
mycin resistant clones were isolated, ten clones were
tested for inducibility by pTet-off (Clontech, Palo Alto,
CA). One clone TLP-10 showed a four-log increase in luci-
ferase expression over background in the presence of
transfected pTet-off (data not shown), and was subse-
quently used for the in vitro studies presented here.
pT2/GT2/tTA/SVNeo was transfected into the TLP-10 cell
line along with pCMV-SB [1], and clones were selected in
800 µg/mL G418. pT2/SVNeo [14] was used as a control.
Fifty of these clones and twelve control clones were grown
to confluency on 60 mm plates and cells harvested with
Promega's Cell Culture Lysis Reagent for luciferase assays.
Luciferase assays were performed on 20 µL of lysis extract
using 100 µL of Promega's Luciferase Assay Substrate and
a Lumat LB 9507 luminometer (Berthold, Bundoora, Aus-
tralia) with a 15 second measuring time. Relative light
unit (RLU) measurements were normalized to total pro-
tein concentration as determined by Bradford assay. Dox-
ycycline (Sigma cat. #D-9891) was added to a final
concentration of 2 mM to repress tTA-induction of TRE-
Luciferase in clones 39, 43, and 44.
RT-PCR and 5' rapid amplification of cDNA ends (RACE)
All primer/oligo sequences for PCR are provided in Addi-
tional file 4. Total RNA from cultured cells or mouse tis-
sues was extracted with Trizol® (Invitrogen, Carlsbad, CA).
RT-PCR was performed using the one-step RobusT™ I RT-
PCR Kit (Finnzymes, Espoo, Finland) according to the
manufacturer's protocol. A template-switching reaction
with Superscript III (Invitrogen) was used to make tem-
plate for 5'RACE on cultured cell or mouse tissue RNA
extract. 250 ng total RNA was mixed with 1 µM each of
primers GT2-RT3 and RACE-1, along with 0.01 M dithio-
threitol, 500 µM dNTPs, and 1 unit of Superscript III. The
mixture was cycled six times at 52°C for 10', 50°C for 15',
and then gradually cooled from 50°C to 37°C over two
minutes before a final extension for 90" at 37°C. Tem-
plate was diluted ten-fold in water and 2 µL was used for
primary 5'RACE PCR. Briefly, the template was amplified
in a 50 µL PCR reaction supplemented with primers GT2-
RT3 (0.4 µM), KJC-002 (0.04 µM) and KJC-003 (0.1 µM),
200 µM dNTPS, 2 mM MgCl2, and 1 unit of Taq DNA
polymerase (CLP, San Diego, CA). The PCR machine was
programmed for touchdown PCR at 95°C for 3', 10 cycles
of 95°C for 30", 65°C for 30" (-0.5°C per cycle), 70°C for
2', and then 25 cycles of 95°C for 30", 60°C for 30", and
70°C for 2'. The primary RACE reaction was diluted 1:50
and 2 µL used in a nested PCR under the same exact con-
ditions, except supplemented with 0.5 µM of each primer
GT2-RT2 and KJC-004.
Generation of T2/GT2/tTA and T2/GT3/tTA mice by 
pronuclear injection, fluorescent in situ hybridization, and 
Southern blotting
The 3379-bp FspI -SapI fragment of pT2/GT2/tTA or the
3738-bp  FspI -SapI fragment of pT2/GT3/tTA were gel-
purified, ethanol precipitated twice, and resuspended in 5
mM Tris-Cl (pH 7.5), 0.1 mM EDTA for pronuclear injec-
tion into the FVB/N strain of mice (Charles River Labora-
tories, Wilmington, MA). The pT2/GT3/tTA fragment was
co-injected with the similarly-prepared HinP1I fragment
of the plasmid pTYBS [Overbeek, 1991 #211], a tyrosinase
minigene construct kindly provided by Dr. Paul Over-
beek, in an attempt to coat-color mark animals that
inherit the transposon/tyrosinase minigene transgenic
insertion site. Expression of the tyrosinase, for unknown
reasons, was not evident in any of the founders (data not
shown). FISH on T2/GT3/tTA transgenic mouse lines was
performed on splenic lymphocytes using standard tech-
niques, and performing nick translation to label the pT2/
GT3/tTA plasmid or whole BAC DNA from the Wellcome
Trust Sanger Institute [46] were used as a probe. Standard
Southern blotting techniques were used to analyze
BamHI-digested genomic DNA from founders and subse-
quent generations using the 842-bp NcoI -SphI fragment
of the tTA open reading frame as a probe. BamHI restricts
each copy in any T2/GT2/tTA or T2/GT3/tTA concatemer
to a single band at 2124-bp or 2236-bp respectively (see
Fig. 1A). Transposons mobilized from the concatemer to
a genomic site are detected as bands of variable size whichBMC Biotechnology 2006, 6:30 http://www.biomedcentral.com/1472-6750/6/30
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are larger than the concatemer band, their size determined
by the nearest genomic BamHI site (see Fig. 5C).
Western blotting for CA-XII expression
Whole kidney extracts were probed with a polyclonal CA-
XII antibody kindly provided by the laboratory of Dr. Wil-
liam Sly. 50 µg total protein was run on a 10% SDS-PAGE
(Invitrogen) and transferred to PVDF and probed with a
1:1000 dilution of anti-CAXII primary antibody followed
by a 1:10000 dilution of horseradish peroxidase-conju-
gated Anti-rabbit IgG secondary (Amersham Biosciences)
in TBST (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 %
Tween 20) supplemented with 1% dry milk.
In vivo luciferase imaging and analysis of luciferase 
expression, doxycycline treatment
Transgenic mice were imaged as described in Wilber, et al
. (2005) [47], using luciferin from Xenogen Corporation
(Alameda, CA). For luciferase assays on organ extracts,
mice were sacrificed, and whole organs dissected and
homogenized in Promega's Cell Culture Lysis Reagent.
Extracts were analyzed as described above for the in vitro
work. Drinking water was supplemented with 5 mg/mL
Doxycycline and 0.1% sodium saccharine for 6 days to
suppress tTA-induced activation.
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Additional File 2
Germline T2/GT2/tTA insertions The genomic positions of thirty T2/
GT2/tTA insertions identified in the offspring of seed mice from line 4563 
(Table 1) are reported. Shown are the chromosome and position, along 
with the identification and description of known or predicted genes poten-
tially disrupted for each insertion. This data is based on the ENSEMBL 
May17, 2005 freeze of the NCBI m34 build.
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Additional File 3
Distribution of thirty T2/GT2/tTA insertions Cloning insertions from 
offspring of seed mice from transgenic line 4563 (Table 1) reveals two 
local hopping intervals, one on mouse chromosome 1 near 45.8 Mb, and 
a second on mouse chromosome-9 around 66.5 Mb. By Southern blot, it 
was later determined that the 4563 line of mice originally obtained and 
segregated two independent concatemer integrations during the initial 
transgenesis (data not shown)
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Additional File 4
Primer sequences
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-6-30-S4.doc]BMC Biotechnology 2006, 6:30 http://www.biomedcentral.com/1472-6750/6/30
Page 15 of 15
(page number not for citation purposes)
using the Sleeping Beauty transposon system.  Nat Methods
2005, 2(10):763-769.
8. Heine HL, Leong HS, Rossi FM, McManus BM, Podor TJ: Strategies
of conditional gene expression in myocardium: an overview.
Methods Mol Med 2005, 112:109-154.
9. Lewandoski M: Conditional control of gene expression in the
mouse.  Nat Rev Genet 2001, 2(10):743-755.
10. Ristevski S: Making better transgenic models: conditional,
temporal, and spatial approaches.  Mol Biotechnol 2005,
29(2):153-163.
11. Duffy JB: GAL4 system in Drosophila: a fly geneticist's Swiss
army knife.  Genesis 2002, 34(1-2):1-15.
12. Gossen M, Bujard H: Tight control of gene expression in mam-
malian cells by tetracycline-responsive promoters.  Proc Natl
Acad Sci U S A 1992, 89(12):5547-5551.
13. Clark KJ, Geurts AM, Bell JB, Hackett PB: Transposon vectors for
gene-trap insertional mutagenesis in vertebrates.  Genesis
2004, 39(4):225-233.
14. Cui Z, Geurts AM, Liu G, Kaufman CD, Hackett PB: Structure-
function analysis of the inverted terminal repeats of the
sleeping beauty transposon.  J Mol Biol 2002, 318(5):1221-1235.
15. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H:
Transcriptional activation by tetracyclines in mammalian
cells.  Science 1995, 268(5218):1766-1769.
16. Dupuy AJ, Fritz S, Largaespada DA: Transposition and gene dis-
ruption in the male germline of the mouse.  Genesis 2001,
30(2):82-88.
17. Fischer SE, Wienholds E, Plasterk RH: Regulated transposition of
a fish transposon in the mouse germ line.  Proc Natl Acad Sci U
S A 2001, 98(12):6759-6764.
18. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K: Deletion of
a DNA polymerase beta gene segment in T cells using cell
type-specific gene targeting.  Science 1994, 265(5168):103-106.
19. Orban PC, Chui D, Marth JD: Tissue- and site-specific DNA
recombination in transgenic mice.  Proc Natl Acad Sci U S A 1992,
89(15):6861-6865.
20. Sauer B: Manipulation of transgenes by site-specific recombi-
nation: use of Cre recombinase.  Methods Enzymol 1993,
225:890-900.
21. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA:
Cancer gene discovery in solid tumours using transposon-
based somatic mutagenesis in the mouse.  Nature 2005,
436(7048):272-276.
22. Halmi P, Lehtonen J, Waheed A, Sly WS, Parkkila S: Expression of
hypoxia-inducible, membrane-bound carbonic anhydrase
isozyme XII in mouse tissues.  Anat Rec 2004, 277A(1):171-177.
23. Hynninen P, Hamalainen JM, Pastorekova S, Pastorek J, Waheed A, Sly
WS, Tomas E, Kirkinen P, Parkkila S: Transmembrane carbonic
anhydrase isozymes IX and XII in the female mouse repro-
ductive organs.  Reprod Biol Endocrinol 2004, 2(1):73.
24. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H,
Bujard H: Doxycycline-mediated quantitative and tissue-spe-
cific control of gene expression in transgenic mice.  Proc Natl
Acad Sci U S A 1996, 93(20):10933-10938.
25. Hasan MT, Schonig K, Berger S, Graewe W, Bujard H: Long-term,
noninvasive imaging of regulated gene expression in living
mice.  Genesis 2001, 29(3):116-122.
26. Pietri T, Thiery JP, Dufour S: Differential expression of beta3
integrin gene in chick and mouse cranial neural crest cells.
Dev Dyn 2003, 227(2):309-313.
27. Lin CM, Chen HJ, Leung CL, Parry DA, Liem RK: Microtubule actin
crosslinking factor 1b: a novel plakin that localizes to the
Golgi complex.  J Cell Sci 2005, 118(Pt 16):3727-3738.
28. Fedorov LM, Tyrsin OY, Krenn V, Chernigovskaya EV, Rapp UR: Tet-
system for the regulation of gene expression during embry-
onic development.  Transgenic Res 2001, 10(3):247-258.
29. Furth PA, St Onge L, Boger H, Gruss P, Gossen M, Kistner A, Bujard
H, Hennighausen L: Temporal control of gene expression in
transgenic mice by a tetracycline-responsive promoter.  Proc
Natl Acad Sci U S A 1994, 91(20):9302-9306.
30. Henikoff S: Conspiracy of silence among repeated transgenes.
Bioessays 1998, 20(7):532-535.
31. Chen WV, Delrow J, Corrin PD, Frazier JP, Soriano P: Identification
and validation of PDGF transcriptional targets by microar-
ray-coupled gene-trap mutagenesis.  Nat Genet 2004,
36(3):304-312.
32. Niwa H, Araki K, Kimura S, Taniguchi S, Wakasugi S, Yamamura K:
An efficient gene-trap method using poly A trap vectors and
characterization of gene-trap events.  J Biochem (Tokyo) 1993,
113(3):343-349.
33. Skarnes WC, Auerbach BA, Joyner AL: A gene trap approach in
mouse embryonic stem cells: the lacZ reported is activated
by splicing, reflects endogenous gene expression, and is
mutagenic in mice.  Genes Dev 1992, 6(6):903-918.
34. Skarnes WC: Gene trapping methods for the identification
and functional analysis of cell surface proteins in mice.  Meth-
ods Enzymol 2000, 328:592-615.
35. Chappell SA, Edelman GM, Mauro VP: A 9-nt segment of a cellular
mRNA can function as an internal ribosome entry site
(IRES) and when present in linked multiple copies greatly
enhances IRES activity.  Proc Natl Acad Sci U S A 2000,
97(4):1536-1541.
36. Gerlitz O, Nellen D, Ottiger M, Basler K: A screen for genes
expressed in Drosophila imaginal discs.  Int J Dev Biol 2002,
46(1):173-176.
37. Martin JR, Keller A, Sweeney ST: Targeted expression of tetanus
toxin: a new tool to study the neurobiology of behavior.  Adv
Genet 2002, 47:1-47.
38. Lemmen JG, Arends RJ, van der Saag PT, van der Burg B: In vivo
imaging of activated estrogen receptors in utero by estro-
gens and bisphenol A.  Environ Health Perspect 2004,
112(15):1544-1549.
39. Lipshutz GS, Gruber CA, Cao Y, Hardy J, Contag CH, Gaensler KM:
In utero delivery of adeno-associated viral vectors: intraperi-
toneal gene transfer produces long-term expression.  Mol
Ther 2001, 3(3):284-292.
40. Baron U, Freundlieb S, Gossen M, Bujard H: Co-regulation of two
gene activities by tetracycline via a bidirectional promoter.
Nucleic Acids Res 1995, 23(17):3605-3606.
41. Krestel HE, Mayford M, Seeburg PH, Sprengel R: A GFP-equipped
bidirectional expression module well suited for monitoring
tetracycline-regulated gene expression in mouse.  Nucleic
Acids Res 2001, 29(7):E39.
42. Huang CJ, Spinella F, Nazarian R, Lee MM, Dopp JM, de Vellis J:
Expression of green fluorescent protein in oligodendrocytes
in a time- and level-controllable fashion with a tetracycline-
regulated system.  Mol Med 1999, 5(2):129-137.
43. Saam JR, Gordon JI: Inducible gene knockouts in the small
intestinal and colonic epithelium.  J Biol Chem 1999,
274(53):38071-38082.
44. Ye L, Chan S, Chow YH, Tsui LC, Hu J: Regulated expression of
the human CFTR gene in epithelial cells.  Mol Ther 2001, 3(5 Pt
1):723-733.
45. Noh MJ, Kim SJ, Kang YK, Yoo OJ: Sequences responsible for
transcription termination of the mouse gastrin gene.  Biochem
Mol Biol Int 1995, 35(6):1205-1213.
46. Adams DJ, Quail MA, Cox T, van der Weyden L, Gorick BD, Su Q,
Chan WI, Davies R, Bonfield JK, Law F, Humphray S, Plumb B, Liu P,
Rogers J, Bradley A: A genome-wide, end-sequenced 129Sv
BAC library resource for targeting vector construction.
Genomics 2005, 86(6):753-758.
47. Wilber A, Frandsen JL, Wangensteen KJ, Ekker SC, Wang X, McIvor
RS: Dynamic gene expression after systemic delivery of plas-
mid DNA as determined by in vivo bioluminescence imag-
ing.  Hum Gene Ther 2005, 16(11):1325-1332.